eIF4E/eIF4G Interaction Inhibitor, 4EGI-1
Modify Date: 2024-01-02 09:34:14
eIF4E/eIF4G Interaction Inhibitor, 4EGI-1 structure
|
Common Name | eIF4E/eIF4G Interaction Inhibitor, 4EGI-1 | ||
|---|---|---|---|---|
| CAS Number | 315706-13-9 | Molecular Weight | 451.28 | |
| Density | 1.6±0.1 g/cm3 | Boiling Point | 712.2±70.0 °C at 760 mmHg | |
| Molecular Formula | C18H12Cl2N4O4S | Melting Point | N/A | |
| MSDS | N/A | Flash Point | 384.5±35.7 °C | |
Use of eIF4E/eIF4G Interaction Inhibitor, 4EGI-14EGI-1 is an inhibitor of eIF4E/eIF4G interaction, with a Kd of 25 μM against eIF4E binding. |
| Name | 2-[[4-(3,4-dichlorophenyl)-4,5-dihydro-1,3-thiazol-2-yl]hydrazinylidene]-3-[2-(dihydroxyamino)phenyl]propanoic acid |
|---|---|
| Synonym | More Synonyms |
| Description | 4EGI-1 is an inhibitor of eIF4E/eIF4G interaction, with a Kd of 25 μM against eIF4E binding. |
|---|---|
| Related Catalog | |
| Target |
Kd: 25 μM (eIF4E/eIF4G)[1] |
| In Vitro | 4EGI-1 is an inhibitor of eIF4E/eIF4G interaction, with a Kd of 25 μM against eIF4E binding. 4EGI-1 disrupts the eIF4F complex and inhibits expression of oncogenic proteins in mammalian cells. 4EGI-1 (0-40 μM) also exhibits proapoptotic activity and inhibits the growth of multiple cancer cell lines[1]. 4EGI-1 is cytotoxic to breast cancer cells, such as SKBR-3, MCF-7 and MDA-MB-231 cells, with the IC50 of appr 30 μM, and to the non-CSCs (Cancer stem cells), the IC50 is about 22 μM. 4EGI-1 enhances breast CSC differentiation (40 μM), and suppresses breast CSC induced HUVEC tube-like structure formation (8 μM). Moreover, 4EGI-1 selectively inhibits translation that persists in CSC maintenance and dissemination[2]. 4EGI-1 (50 µM) impairs the formation of eIF4F complex in U87 cells. 4EGI-1 (10, 50 and 100 µM) inhibits cell proliferation via inducing apoptosis in U87 cells, and the apoptosis is via Bax activation. 4EGI-1 causes mitochondrial dysfunction, and induces ER stress via GRP-78 activation, in U87 cells[3]. |
| In Vivo | 4EGI-1 (75 mg/kg, i.p.) inhibits breast cancer stem cells (CSC) tumor growth and tumorangiogenesis in vivo[2]. 4EGI-1 (75 mg/kg, i.p.) shows inhibitory effect on the tumor volume and weight in mice bearing U87 cells[3]. |
| Cell Assay | 1 × 104 breast CSCs HMLER (CD44high/CD24low)FA cells and other indicated breast cancer cells are treated with DMSO, or [E]-4EGI-1 or [Z]-4EGI-1 at series of concentrations for 24 hours. The cells are performed cell viability assays with cell viability assay kit. Three independent experiments are performed. Average IC50 results are shown (mean ± SD, t-test, two-tailed)[2]. |
| Animal Admin | Mice[2] In the tumor xenografted assay, 1×105 breast cancer stem cells (CSCs) are mixed with 100 μL Matrigel/DMEM mixture (Matrigel: DMEM = 1:2). Breast CSCs/Matrigel/DMEM mixtures are injected into NOD/SCID female mice mammary glands by subcutaneous injection. After the tumor formation (about 75 mm3 in volume, 5 mice/group), DMSO, or 75 mg/kg [E]-4EGI-1, or 75 mg/kg [Z]-4EGI-1 is injected into the mice by intraperitoneal injection daily for 30 days. Tumor volumes are measured every three days. At the 30th day, mice are sacrificed and tumors are excised. Tumors weights are measured. Tumor tissue samples are used for immunohistostaining, Western blot and immunoprecipitation analyses[2]. |
| References |
| Density | 1.6±0.1 g/cm3 |
|---|---|
| Boiling Point | 712.2±70.0 °C at 760 mmHg |
| Molecular Formula | C18H12Cl2N4O4S |
| Molecular Weight | 451.28 |
| Flash Point | 384.5±35.7 °C |
| PSA | 143.05000 |
| LogP | 2.46 |
| Vapour Pressure | 0.0±2.4 mmHg at 25°C |
| Index of Refraction | 1.714 |
| Storage condition | -20℃ |
|
~65%
eIF4E/eIF4G Int... CAS#:315706-13-9 |
| Literature: Wagner, Gerhard; Chorev, Michael; Moerke, Nathan; Aktas, Huseyin; Halperin, Jose Patent: US2010/144805 A1, 2010 ; Location in patent: Page/Page column 15; 16 ; |
| Precursor 2 | |
|---|---|
| DownStream 0 | |
| (2Z)-2-{[4-(3,4-Dichlorophenyl)-4,5-dihydro-1,3-thiazol-2-yl]hydrazono}-3-[2-(dihydroxyamino)phenyl]propanoic acid |
| eIF4E/eIF4G Interaction Inhibitor,4EGI-1 |
| Benzenepropanoic acid, α-[2-[4-(3,4-dichlorophenyl)-4,5-dihydro-2-thiazolyl]hydrazinylidene]-2-(dihydroxyamino)-, (αZ)- |
| 4EGI-1 |